MedTrace Logo

Multicentre Study in Four Parallel Groups of Parkinson's Disease (PD) Patients

NCT01568047 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2015-12-24

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to investigate the tolerability and the effect of BIA 9-1067 at steady-state on the levodopa pharmacokinetics in Parkinson's Disease (PD) patients treated with levodopa/dopa-decarboxylase inhibitor.

Conditions

Interventions

DRUG

Placebo

once-daily

DRUG

BIA 9-1067

BIA 9-1067 - 5 mg single-dose

DRUG

BIA 9-1067

BIA 9-1067 - 15 mg single-dose

DRUG

BIA 9-1067

BIA 9-1067 - 30 mg single-dose

DRUG

Levodopa/Carbidopa

Levodopa 100 mg Carbidopa 25 mg

DRUG

Levodopa/Benzerazide

Levodopa 100 mg Benzerazide 25 mg

Sponsors & Collaborators

  • Bial - Portela C S.A.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-02-28
Primary Completion
2010-06-30
Completion
2010-06-30

Countries

  • Romania
  • Ukraine

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01568047 on ClinicalTrials.gov